[HTML][HTML] Efficacy differences of pemetrexed by histology in pretreated patients with stage IIIB/IV non-small cell lung cancer: review of results from an open-label …
K Kubota, S Niho, S Enatsu, Y Nambu… - Journal of Thoracic …, 2009 - Elsevier
Introduction Recent pivotal phase III studies in patients with advanced non-small cell lung
cancer (NSCLC) consistently showed greater survival benefit of pemetrexed in patients with …
cancer (NSCLC) consistently showed greater survival benefit of pemetrexed in patients with …
Efficacy Differences of Pemetrexed by Histology in Pretreated Patients with Stage IIIB/IV Non-small Cell Lung Cancer: Review of Results from an Open-Label …
K Kubota, S Niho, S Enatsu, Y Nambu… - Journal of Thoracic …, 2009 - jto.org
Introduction Recent pivotal phase III studies in patients with advanced non-small cell lung
cancer (NSCLC) consistently showed greater survival benefit of pemetrexed in patients with …
cancer (NSCLC) consistently showed greater survival benefit of pemetrexed in patients with …
[引用][C] Efficacy Differences of Pemetrexed by Histology in Pretreated Patients with Stage IIIB/IV Non-small Cell Lung Cancer: Review of Results from an Open-Label …
K Kubota, S Niho, S Enatsu, Y Nambu… - Journal of Thoracic …, 2009 - cir.nii.ac.jp
Efficacy Differences of Pemetrexed by Histology in Pretreated Patients with Stage IIIB/IV Non-small
Cell Lung Cancer: Review of Results from an Open-Label Randomized Phase II Study | CiNii …
Cell Lung Cancer: Review of Results from an Open-Label Randomized Phase II Study | CiNii …
Efficacy differences of pemetrexed by histology in pretreated patients with stage IIIB/IV non-small cell lung cancer: review of results from an open-label randomized …
K Kubota, S Niho, S Enatsu, Y Nambu… - Journal of Thoracic …, 2009 - europepmc.org
Methods Objective response rates (ORRs), overall survival time, and progression-free
survival time were analyzed by subgroup of histology, squamous, and nonsquamous, for the …
survival time were analyzed by subgroup of histology, squamous, and nonsquamous, for the …
[PDF][PDF] Efficacy Differences of Pemetrexed by Histology in Pretreated Patients with Stage IIIB/IV Non-small Cell Lung Cancer
K Kubota, S Niho, S Enatsu, Y Nambu, Y Nishiwaki… - Methods, 2008 - core.ac.uk
Methods: Objective response rates (ORRs), overall survival time, and progression-free
survival time were analyzed by subgroup of histology, squamous, and nonsquamous, for the …
survival time were analyzed by subgroup of histology, squamous, and nonsquamous, for the …
Efficacy differences of pemetrexed by histology in pretreated patients with stage IIIB/IV non-small cell lung cancer: review of results from an open-label randomized …
K Kubota, S Niho, S Enatsu… - Journal of thoracic …, 2009 - pubmed.ncbi.nlm.nih.gov
Introduction Recent pivotal phase III studies in patients with advanced non-small cell lung
cancer (NSCLC) consistently showed greater survival benefit of pemetrexed in patients with …
cancer (NSCLC) consistently showed greater survival benefit of pemetrexed in patients with …